Literature DB >> 17527070

Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors.

Sandro Santagata1, Keith L Ligon, Jason L Hornick.   

Abstract

The core embryonic stem cell transcription factors (TFs) OCT3/4 (OCT4), NANOG, and SOX2 have shared as well as nonoverlapping roles in stem cell growth and differentiation. These same TFs are also expressed in various types of human germ cell tumors (GCTs), implicating them in regulation of tumor growth and differentiation. Although NANOG and OCT3/4 are sensitive and specific markers for seminoma and embryonal carcinoma, neither factor aids in the clinically important distinction of seminomatous from nonseminomatous tumors. In contrast, expression profiling data suggest that SOX2 may help with this distinction. To determine if a panel of embryonic stem cell TFs (NANOG, OCT3/4, and SOX2) can facilitate the identification and distinction of seminomatous from nonseminomatous GCTs, we evaluated their expression by immunohistochemistry in primary testicular (n=41) and metastatic retroperitoneal (n=43) GCTs. Our results confirm NANOG and OCT3/4 as sensitive and specific markers for primary seminoma and embryonal carcinoma and demonstrate the novel finding that NANOG is a marker for metastatic GCTs. In addition, SOX2 is expressed in embryonal carcinoma but not pure seminoma and is therefore a useful diagnostic marker for distinguishing seminomatous and nonseminomatous GCTs. In summary, we find that the embryonic stem cell TF signature of seminoma is NANOG+, OCT3/4+, and SOX2-, whereas embryonal carcinoma is NANOG+, OCT3/4+, and SOX2+, and expect these immunohistochemical profiles will facilitate the diagnosis of both primary and metastatic GCTs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17527070     DOI: 10.1097/PAS.0b013e31802e708a

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  51 in total

1.  Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors.

Authors:  Samuel A Funt; Sujata Patil; Darren R Feldman; Robert J Motzer; Dean F Bajorin; Joel Sheinfeld; Satish K Tickoo; Victor E Reuter; George J Bosl
Journal:  J Clin Oncol       Date:  2019-06-24       Impact factor: 44.544

2.  Oct4 dependence of chromatin structure within the extended Nanog locus in ES cells.

Authors:  Dana N Levasseur; Jianlong Wang; Michael O Dorschner; John A Stamatoyannopoulos; Stuart H Orkin
Journal:  Genes Dev       Date:  2008-02-18       Impact factor: 11.361

3.  Expression of Sox2 in human ovarian epithelial carcinoma.

Authors:  Feng Ye; Yanli Li; Ying Hu; Caiyun Zhou; Yuting Hu; Huaizeng Chen
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-27       Impact factor: 4.553

4.  Tumor-initiating stem-like cells and drug resistance: carcinogenesis through Toll-like receptors, environmental factors, and virus.

Authors:  Keigo Machida
Journal:  Drug Deliv Transl Res       Date:  2013-04       Impact factor: 4.617

5.  A basal stem cell signature identifies aggressive prostate cancer phenotypes.

Authors:  Bryan A Smith; Artem Sokolov; Vladislav Uzunangelov; Robert Baertsch; Yulia Newton; Kiley Graim; Colleen Mathis; Donghui Cheng; Joshua M Stuart; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

6.  SALL4 is a useful marker in the diagnostic work-up of germ cell tumors in extra-testicular locations.

Authors:  Philippe Camparo; Eva Maria Comperat
Journal:  Virchows Arch       Date:  2012-12-09       Impact factor: 4.064

7.  Oct4A is expressed by a subpopulation of prostate neuroendocrine cells.

Authors:  Paula Sotomayor; Alejandro Godoy; Gary J Smith; Wendy J Huss
Journal:  Prostate       Date:  2009-03-01       Impact factor: 4.104

8.  Establishment and characterization of a new human extragonadal germ cell line, SEM-1, and its comparison with TCam-2 and JKT-1.

Authors:  Sarah M Russell; Melissa G Lechner; Anusuya Mokashi; Carolina Megiel; Julie K Jang; Clive R Taylor; Leendert H J Looijenga; Christopher A French; Alan L Epstein
Journal:  Urology       Date:  2013-02       Impact factor: 2.649

9.  SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.

Authors:  Adam J Bass; Hideo Watanabe; Craig H Mermel; Soyoung Yu; Sven Perner; Roel G Verhaak; So Young Kim; Leslie Wardwell; Pablo Tamayo; Irit Gat-Viks; Alex H Ramos; Michele S Woo; Barbara A Weir; Gad Getz; Rameen Beroukhim; Michael O'Kelly; Amit Dutt; Orit Rozenblatt-Rosen; Piotr Dziunycz; Justin Komisarof; Lucian R Chirieac; Christopher J Lafargue; Veit Scheble; Theresia Wilbertz; Changqing Ma; Shilpa Rao; Hiroshi Nakagawa; Douglas B Stairs; Lin Lin; Thomas J Giordano; Patrick Wagner; John D Minna; Adi F Gazdar; Chang Qi Zhu; Marcia S Brose; Ivan Cecconello; Ulysses Ribeiro; Suely K Marie; Olav Dahl; Ramesh A Shivdasani; Ming-Sound Tsao; Mark A Rubin; Kwok K Wong; Aviv Regev; William C Hahn; David G Beer; Anil K Rustgi; Matthew Meyerson
Journal:  Nat Genet       Date:  2009-10-04       Impact factor: 38.330

10.  CRX is a diagnostic marker of retinal and pineal lineage tumors.

Authors:  Sandro Santagata; Cecile L Maire; Ahmed Idbaih; Lars Geffers; Mick Correll; Kristina Holton; John Quackenbush; Keith L Ligon
Journal:  PLoS One       Date:  2009-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.